Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Circulation · 21.05.2024 · 149 (21) · 1627-1638
DOI: 10.1161/circulationaha.124.069217 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 21.05.2024. Verfasst von Adrian F Hernandez und 41 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Department of Medicine, Division of Cardiology, and Duke Clinical Research Institute, Durham, NC (A.F.H., W.S.J., J.H., R.D.L.). Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Heart Failure, Myocardial Infarction. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim and Eli Lilly and Company.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown. METHODS: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University Department of Medicine, Division of Cardiology, and Duke Clinical Research Institute, Durham, NC (A.F.H., W.S.J., J.H., R.D.L.).
- Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Canada (J.A.U.).
- Department of Cardiology (CVK) of German Heart Center Charité, Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universit…
- School of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, UK (M.C.P.).
- Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany (M.M., S.S., I.Z.).
- Heart Institute, Hadassah Medical Center, The Hebrew University of Jerusalem, Israel (O.A.).
ORCID-Profile: Jacob A Udell, W Schuyler Jones, Stefan D Anker, Mark C Petrie, Josephine Harrington, Michaela Mattheus, Isabella Zwiener, Offer Amir, M Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Yundai Chen, Vijay K Chopra, Gemma A Figtree, Shaun G Goodman, Nina Gotcheva, Shinya Goto, James L Januzzi, Yuri Lopatin, Renato D Lopes, Puja B Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rossello, Morten Schou, Dragan Simic, Philippe Gabriel Steg, Peter van der Meer, Dragos Vinereanu, Martina Brueckmann, Mikhail Sumin, Deepak L Bhatt, Javed Butler
Förderung
- Boehringer Ingelheim and Eli Lilly and Company
Zitieren
APA
Hernandez, A. F., Udell, J. A., Jones, W. S., Anker, S. D., Petrie, M. C., Harrington, J., Mattheus, M., Seide, S., Zwiener, I., Amir, O., Bahit, M. C., Bauersachs, J., Bayes-Genis, A., Chen, Y., Chopra, V. K., A Figtree, G., Ge, J., G Goodman, S., Gotcheva, N., …, & Butler, J. (2024). Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation, 149(21), 1627-1638. https://doi.org/10.1161/circulationaha.124.069217
Vancouver
Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J, et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024;149(21):1627-1638. doi:10.1161/circulationaha.124.069217
BibTeX
@article{Hernandez2024,
author = {Hernandez, Adrian F and Udell, Jacob A and Jones, W Schuyler and Anker, Stefan D and Petrie, Mark C and Harrington, Josephine and Mattheus, Michaela and Seide, Svenja and Zwiener, Isabella and Amir, Offer and Bahit, M Cecilia and Bauersachs, Johann and Bayes-Genis, Antoni and Chen, Yundai and Chopra, Vijay K and A Figtree, Gemma and Ge, Junbo and G Goodman, Shaun and Gotcheva, Nina and Goto, Shinya and Gasior, Tomasz and Jamal, Waheed and Januzzi, James L and Jeong, Myung Ho and Lopatin, Yuri and Lopes, Renato D and Merkely, Béla and Parikh, Puja B and Parkhomenko, Alexander and Ponikowski, Piotr and Rossello, Xavier and Schou, Morten and Simic, Dragan and Steg, Philippe Gabriel and Szachniewicz, Joanna and van der Meer, Peter and Vinereanu, Dragos and Zieroth, Shelley and Brueckmann, Martina and Sumin, Mikhail and Bhatt, Deepak L and Butler, Javed},
title = {Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial},
journal = {Circulation},
year = {2024},
volume = {149},
number = {21},
pages = {1627--1638},
doi = {10.1161/circulationaha.124.069217}
}
EUVIMED